Matinas BioPharma Investor Presentation Deck
26
Summary of Recent Key Advances
Successful in vivo oral delivery of LNC-Docetaxel in a melanoma tumor model
• Reductions in tumor weight and volume comparable to those seen with IV docetaxel
No adverse effects on body weight or hematologic parameters
► Successful in vivo oral delivery of LNC formulations of 2 different RNAi oligonucleotides targeting
inflammatory cytokines
• Documented biological activity and therapeutic impact in two different disease models.
- Psoriasis (IL-17A)
●
Reduction in tissue IL-17A mRNA levels (skin)
Statistically significant improvement in clinical scoring of skin lesions
Colitis (TNFa)
●
●
●
●
Reductions in tissue TNFa mRNA levels (colon)
Statistically significant reductions in serum TNFx levels
Statistically significant improvement in disease activity scores
COPYRIGHT MATINAS BIOPHARMA
2024
These results highlight and validate the unique
capabilities of the LNC platform beyond MAT2203
1) Oral delivery
2) Delivery of active therapeutics (small
molecule and small oligo) to diseased
tissues outside the liver
3) Low blood levels of active drug, with
potential for improved safety
MATINAS
BIOPHARMAView entire presentation